Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMD
Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related macular degeneration (AMD).
The phase 1 study of IBI302 is an open-label, single-center, dose escalation clinical trial to evaluate the safety and tolerability of IBI302 in a single intravitreal injection in patients with wet AMD.
“Antibody drugs targeting vascular endothelial growth factor A (VEGF-A) have now become the standard first-line treatment of neovascular ocular fundus diseases. However, an antibody-like bi-specific fusion protein drug targeting both VEGF and complement proteins has not been studied in clinical trials anywhere in the world,” Professor Xiaodong Sun of the Shanghai General Hospital Affiliated to Shanghai Jiao Tong University said in a company news release. “IBI302, an innovative first-in-class category 1 innovative drug candidate developed by Innovent for the treatment of ocular fundus diseases, has been supported by ‘The National Major New Drugs Innovation and Development Projects.’ We believe IBI302 can potentially become a breakthrough therapy and provide a new treatment option for patients in need.”
“Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision impairment among China’s elderly population. Although the efficacy of current therapies for wet AMD is adequate, there are still huge unmet medical needs in terms of injection frequency and long-term prognosis for patients. As the world’s first antibody-like bi-specific fusion complement protein for ocular fundus diseases, IBI302 is designed to cure AMD by attacking its root causes in addition to relieving the symptoms. Hopefully, through our efforts, IBI302 can benefit AMD patients and their families,” Michael Yu, Founder, Chief Executive Officer, and Chairman of Innovent, said in the news release.